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INTRODUCTION
The number of end-stage renal disease (ESRD) patients 
requiring dialysis treatment has been continuously and 
rapidly increasing over the past few decades. Although 
there is little controversy that kidney transplantation is 
the best renal replacement treatment for ESRD, there 
are many obstacles to its timely initiation, including a 
shortage of donated organs, cultural differences, or poor 
socioeconomic status. Consequently, more than 95% of 
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Background/Aims: Since comorbidities are major determinants of modality 
choice, and also interact with dialysis modality on mortality outcomes, we exam-
ined the pattern of modality choice according to comorbidities and then evalu-
ated how such choices affected mortality in incident dialysis patients. 
Methods: We analyzed 32,280 incident dialysis patients in Korea. Patterns in 
initial dialysis choice were assessed by multivariate logistic regression analyses. 
Multivariate Poisson regression analyses were performed to evaluate the effects 
of interactions between comorbidities and dialysis modality on mortality and to 
quantify these interactions using the synergy factor. 
Results: Prior histories of myocardial infarction (p = 0.031), diabetes (p = 0.001), 
and congestive heart failure (p = 0.003) were independent factors favoring the ini-
tiation with peritoneal dialysis (PD), but were associated with increased mortality 
with PD. In contrast, a history of cerebrovascular disease and 1-year increase in 
age favored initiation with hemodialysis (HD) and were related to a survival ben-
efit with HD (p < 0.001, both). While favoring initiation with HD, having Medical 
Aid (p = 0.001) and male gender (p = 0.047) were related to increased mortality with 
HD. Furthermore, although the severity of comorbidities did not inf luence di-
alysis modality choice, mortality in incident PD patients was significantly higher 
compared to that in HD patients as the severity of comorbidities increased (p for 
trend < 0.001). 
Conclusions: Some comorbidities exerted independent effects on initial choice of 
dialysis modality, but this choice did not always lead to the best results. Further 
analyses of the pattern of choosing dialysis modality according to baseline co-
morbid conditions and related consequent mortality outcomes are needed.
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incident ESRD patients are forced to initiate dialysis 
treatment with hemodialysis (HD) or peritoneal dialysis 
(PD) [1]. In this situation, choice of dialysis modality is 
particularly important and known to be influenced by 
various factors such as geography, patient characteris-
tics and preferences, and medical conditions [2]. Among 
these factors, the patients’ underlying comorbidities 
are found to be the major independent determinants 
of dialysis modality choice [3]. Furthermore, these pre-
existing comorbidities showed significant interactions 
with dialysis modality on patients’ outcomes [4,5]. In this 
light, despite the relevance of surveying the nationwide 
patterns of dialysis modality choice according to under-
lying comorbidities and examining associated clinical 
outcomes, only a few studies have addressed this rela-
tionship [6]. 
We previously reported that, although it is being im-
proved in recent years [7], PD is generally inferior to 
HD as an initial dialysis modality in Korea in terms of 
overall survival, and this is largely accounted for by the 
higher incidence of all-cause mortality, non-fatal acute 
myocardial infarction (MI), and vascular complications 
requiring target vessel revascularization [8,9] in inci-
dent PD patients. This finding was in contrast to recent 
studies of large-scale registry data, but the reasons for 
this inferiority of PD could not be adequately explained 
[10-12]. Therefore, in this study, we approached this is-
sue first by assessing the pattern of modality choice for 
incident dialysis patients according to baseline comor-
bid conditions in Korea, and then evaluated how such 
choice affected mortality outcomes by calculating the 
synergy factor (SF) from the interaction analysis based 
on a multiplicative scale between the various comorbid 
conditions and dialysis modality [13]. 
METHODS
Data source and study population
We used the Korean Health Insurance Review and As-
sessment Service (HIRA) database. The detail of HIRA 
database organization was described elsewhere [9]. The 
Institutional Review Board at the HIRA approved our 
use of the database for this study (IRB No. 3159, 2012).
We initially screened all Korean incident dialysis 
patients who started dialysis therapy between January 
1, 2005 and December 31, 2008. Among them, we only 
included patients who initiated dialysis treatment dur-
ing the study period and remained on chronic dialysis 
therapy for at least 3 months. We excluded patients who 
were younger than 18 years. Finally, our study included 
32,280 eligible patients. Further, we included both the 
patients who have National Health Insurance and those 
who have Medical Aid as primary insurance; Medical 
Aid is a public assistance program for poor individuals 
who are under the National Basic Livelihood Security 
System in Korea as a part of the social welfare programs 
[14]. In all analyses for comparisons between dialysis 
modalities, an intention-to-treat principle was adopted.
The comorbid conditions of the participants were 
identified by screening the medical records during the 
year before the initiation of dialysis therapy. The list of 
comorbidities was determined and scored based on the 
suggestions of Charlson et al. [15], and ICD-10 (Inter-
national Classification of Diseases 10th revision) codes 
were used according to the algorithms proposed by 
Quan et al. [16]. 
Measurements and analyses of outcomes
The primary clinical endpoint of interest for our study 
was all-cause mortality. For assessing event-free surviv-
al, we considered the dialysis modality at day 90 to be 
the initial dialysis modality and used day 90 as the start-
ing point (day 0). That is, the patients analyzed in this 
study were left-censored for the first event-free 90 days 
after dialysis initiation, and they were right-censored at 
December 31, 2009.
Statistical analysis
In comparison analyses, baseline parameters were com-
pared using an independent t test for continuous vari-
ables and Pearson chi-square test for categorical variables. 
There was no missing data on baseline characteristics of 
participants and their outcomes. Crude incidence rates 
of mortality were calculated by dividing the number of 
deaths by the person-years of follow-up, expressed as 
deaths per 1,000 patient-years; confidence intervals (CIs) 
were estimated based on a Poisson distribution.
Multivariable-adjusted logistic regression analyses 
were conducted to estimate odds ratios for the likeli-
hood of choosing an initial dialysis modality between 
two modalities according to the presence or absence of 
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particular comorbid conditions. Cox proportional haz-
ard regression analyses were performed to evaluate the 
increase in the absolute mortality risk associated with 
an initial dialysis modality according to the baseline co-
morbid conditions.
In addition, to assess the degree of change in the rel-
ative risk (RR) for mortality via effect modification be-
tween dialysis modality and various baseline comorbid 
conditions, interaction terms were constructed and en-
tered into multivariable-adjusted Poisson regression 
analyses to test the statistical significance of these in-
teractions on mortality. Furthermore, we quantified the 
degrees of these interactions in terms of SF with 95% 
CIs, based on a multiplicative scale. In brief, SF was cal-
culated from the adjusted RRs. We first estimated the 
RRs for factor x1 alone (RR1), factor x2 alone (RR2), and 
both factors combined (RR12). SF was then defined as the 
ratio of the observed RR for both factors combined and 
presented as SF = RR12 / (RR1 × RR2). Thus, if SF > 1, this 
was interpreted as a positive interaction (a synergistic 
increase in the risk) between the two risk factors [13].
All statistical tests were evaluated using a two-tailed 
95% CI, and p < 0.05 was considered statistically signifi-
cant. All statistical analyses were conducted using the 
statistical package SAS version 9.3 (SAS Institute Inc., 
Cary, NC, USA).
RESULTS
Baseline characteristics
A total of 32,280 eligible patients who initiated dialysis 
therapy between January 1, 2005 and December 31, 2008, 
were analyzed. When comparing patients who initiated 
dialysis therapy with PD versus HD, incident PD pa-
tients were significantly more likely to be younger and 
female, and more likely to have National Health Insur-
ance (vs. Medical Aid) than incident HD patients. While 
the prevalence of diabetes and chronic pulmonary dis-
ease (CPD) was similar, the overall distribution of co-
morbid conditions was significantly different between 
patients on PD and those on HD (Table 1). The severity 
of comorbidities assessed by the Charlson comorbidity 
index (CCI) was also significantly different, and a high 
comorbidity burden (CCI ≥ 3) was significantly more 
prevalent in incident HD patients than in incident PD 
patients. During the median follow-up of 24.5 months 
(range, 3.1 to 59.0) and 67,541 patient-years, 7,820 deaths 
were observed, for an overall estimated death rate of 116 
deaths (95% CI, 113 to 118) per 1,000 patient-years.
Comparison of the absolute mortality risk between PD 
and HD according to baseline comorbid conditions
As shown in Fig. 1, we performed Cox proportional re-
gression analyses and found that overall absolute mor-
tality risk adjusted for all baseline covariates listed in 
Table 1 was significantly 23% higher in the patients ini-
tiating dialysis with PD than those with HD. Then, we 
explored whether this trend was also apparent in various 
subgroups according to baseline comorbid conditions, 
and found that the patients initiating dialysis with PD 
generally have a significant higher absolute risk for mor-
tality than those with HD across all subgroups. However, 
some exceptions were noted; there were no significant 
differences in mortality rates between PD and HD in the 
patients with age < 60 years, Medical Aid as their primary 
insurance, liver disease, cancer, or no comorbidity. 
The pattern of choosing dialysis modality according 
to each comorbid condition and related mortality 
outcomes in all incident dialysis patients
First, we examined which baseline comorbid conditions 
were independently associated with the choice of a par-
ticular dialysis modality in all incident dialysis patients. 
After adjusting for all baseline conditions listed in Table 
1, prior histories of MI, congestive heart failure (CHF), 
and diabetes were independently associated with a high-
er likelihood of receiving PD as an initial dialysis mo-
dality, whereas prior histories of cancer, cerebrovascular 
disease (CVD), and liver disease; Medical Aid as primary 
insurance; male gender; and a 1-year increase in age 
were independently associated with a higher likelihood 
of receiving HD as an initial dialysis modality (Table 2, 
Fig. 2, black bars).
Next, as shown by p values of interaction analyses in 
Fig. 1, we found that the relative degrees of risk for mor-
tality increased by PD were significantly modified by the 
presence or absence of a particular comorbid condition. 
Therefore, we further examined the effects of these in-
teractions between the independent determinants of 
initial modality choice and various baseline comorbid 
conditions on mortality (Table 3, Fig. 2, red bars). Among 
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the independent determinants that led to the choice of 
PD as an initial modality, prior histories of MI, diabetes, 
and CHF showed a significant positive interaction with 
the initiation of dialysis with PD; that is, increased the 
risk of mortality when initiating dialysis treatment with 
PD. On the other hand, having Medical Aid as primary 
insurance and male gender were significant indepen-
dent determinants of dialysis initiation with HD, and 
these choice patterns were eventually associated with a 
synergistically increased risk of mortality. In contrast, a 
history of CVD and a 1-year increase in age, which were 
significant independent determinants of dialysis initia-
tion with HD, were associated with worse survival with 
PD (better survival with HD) (Table 3, Fig. 2). 
The pattern of choosing dialysis modality according 
to each comorbid condition and related mortality 
outcomes in all incident dialysis patients < 60 years
When stratifying by age, we found that, in patients 
younger than 60 years, prior histories of MI, CHF, 
CPD, and diabetes were independently associated with 
a higher likelihood of receiving PD as an initial dialysis 
modality, whereas having Medical Aid as their primary 
insurance, male gender, a history of cancer, and a 1-year 
increase in age were independently associated with a 
higher likelihood of receiving HD as an initial dialysis 
modality (Supplementary Table 1). 
The consequences of this choice are shown in Supple-
mentary Table 2 and indicate that, among the determi-
nants independently associated with the choice of PD 
as an initial modality, prior histories of MI and diabe-
tes synergistically increased the risk of mortality when 
Table 1. Baseline characteristics of the participants
Variable
All incident dialysis patients
(n = 32,280)
Incident PD patients
(n = 7,881)
Incident HD patients
(n = 24,399)
p value
(PD vs. HD)
Age, yr 57.0 ± 13.8 54.2 ± 13.6 57.8 ± 13.8 < 0.001
≥ 60 14,706 (45.6) 2,968 (37.7) 11,738 (48.1) < 0.001
Sex, female (vs. male) 13,337 (41.3) 3,443 (43.7) 9,894 (40.6) < 0.001
NHI (vs. MA) 27,859 (86.3) 6,898 (87.5) 20,961 (85.9) < 0.001
Diabetes mellitus 16,186 (50.1) 3,996 (50.7) 12,190 (50.0) 0.251
Comorbidities other than DM
Myocardial infarction 1,164 (3.6) 367 (4.7) 797 (3.3) < 0.001
Congestive heart failure 4,752 (14.7) 1,269 (16.1) 3,483 (14.3) < 0.001
Peripheral artery disease 1,908 (5.9) 424 (5.4) 1,484 (6.1) 0.022
Cerebrovascular disease 4,038 (12.5) 830 (10.5) 3,208 (13.1) < 0.001
Chronic pulmonary disease 5,221 (16.2) 1,233 (15.6) 3,988 (16.3) 0.142
Peptic ulcer disease 4,709 (14.6) 1,072 (13.6) 3,637 (14.9) 0.004
Liver disease 3,460 (10.7) 780 (9.9) 2,680 (11.0) 0.007
Cancer 1,968 (6.1) 321 (4.1) 1,647 (6.8) < 0.001
CCI 2.2 ± 1.9 2.2 ± 1.9 2.3 ± 1.9 < 0.001
Distribution of CCI scores
0 7,618 (23.6) 1,918 (24.3) 5,700 (23.4) 0.076
1 5,424 (16.8) 1,336 (17.0) 4,088 (16.8) 0.684
2 5,731 (17.8) 1,464 (18.6) 4,267 (17.5) 0.028
≥ 3 13,507 (41.8) 3,163 (40.1) 10,344 (42.4) < 0.001
Values are presented as mean ± SD or number (%).
PD, peritoneal dialysis; HD, hemodialysis; NHI, National Health Insurance; MA, Medical Aid; DM, diabetes mellitus; CCI, 
Charlson comorbidity index.
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starting dialysis treatment with PD. On the other hand, 
among the determinants independently associated with 
the choice of HD as an initial modality, having Medical 
Aid as their primary insurance synergistically increased 
the risk of mortality when starting dialysis treatment 
with HD. In contrast, a 1-year increase in age, which was 
a significant independent determinant of dialysis initi-
ation with HD, was associated with worse survival with 
PD (better survival with HD) (Supplementary Table 2). 
The pattern of choosing dialysis modality according 
to each comorbid condition and related mortality 
outcomes in all incident dialysis patients ≥ 60 years
In patients aged 60 years or older, prior histories of MI 
and CHF were independently related to the choice of PD 
as an initial dialysis modality, whereas prior history of 
cancer, liver disease, or CVD; male gender; and a 1-year 
increase in age were independently associated with a 
higher likelihood of receiving HD as an initial dialysis 
modality (Supplementary Table 3). Among the signif-
icant determinants that led to the choice of PD as an 
initial modality, a prior history of CHF was significantly 
related to the synergistically increased risk of mortality 
when combined with the initiation of dialysis treatment 
on PD. On the other hand, among the significant deter-
minants that led to the choice of HD as an initial mo-
dality, a prior history of cancer and male gender were 
significantly related to the synergistically increased risk 
of mortality when combined with the initiation of dialy-
sis treatment on HD (Supplementary Table 4). 
The pattern of choosing dialysis modality according to 
the severity and number of comorbidities and related 
mortality outcomes
Finally, we sought to evaluate the interaction effects be-
tween the pattern of modality choice and the severity 
and number of comorbidities on mortality outcomes. 
As shown in Table 4, Fig. 3, there was no significant 
difference in the odds of choice for either type of di-
alysis modality according to the severity of comorbid-
ities assessed by CCI or the number of comorbidity (≥ 
1 comorbidities vs. no comorbidity). However, looking 
at the consequences of such choice, we found that, as 
the severity and the number of comorbidities increased, 
the mortality risks of patients initiating dialysis therapy 
with PD were significantly increased compared to those 
initiating with HD; this trend was evident even from a 
CCI score of 1 or higher (p for trend < 0.001) (Table 5, 
Fig. 4).
DISCUSSION
In the current study, we found that some comorbid con-
ditions were independently related to the choice of dial-
ysis modality, and that this choice might not always lead 
to the best mortality outcome. Instead, such choices of-
ten synergistically increased mortality. To approach this 
issue is far from simple because preexisting comorbid-
ity conditions are not the only determinant of dialysis 
All
Age < 60 years
 Age ≥ 60 years
1.23 (1.17-1.29)
1.09 (1.00-1.18)
1.31 (1.24-1.40) < 0.001
0.042
0.001
0.001
0.030
0.003
0.683
< 0.001
0.392
0.351
0.247
0.182
< 0.001
0.5 1.0 1.5 2.0
1.31 (1.22-1.41)
1.17 (1.10-1.25)
1.29 (1.23-1.37)
0.95 (0.84-1.08)
1.15 (1.06-1.25)
1.27 (1.19-1.35)
1.21 (1.15-1.28)
1.40 (1.17-1.69)
1.19 (1.12-1.26)
1.36 (1.22-1.51)
1.22 (1.16-1.29)
1.30 (1.08-1.56)
1.18 (1.12-1.25)
1.46 (1.30-1.63)
1.22 (1.15-1.29)
1.26 (1.13-1.41)
1.22 (1.16-1.29)
1.28 (1.13-1.45)
1.25 (1.18-1.31)
1.10 (0.95-1.28)
1.25 (1.18-1.31)
0.93 (0.78-1.12)
0.95 (0.82-1.10)
1.24 (1.18-1.31)
p for interactionHR (95% CI)
Female
Male
NHI
MA
No DM
DM
No MI
MI
No CHF
CHF
No PAD
PAD
No CVD
CVD
No CPD
CPD
No PUD
PUD
No LD
LD
No cancer
cancer
No comorbidity
 ≥ 1 comorbidities
More harm
from HD
More harm
from PD
Figure 1. Comparisons of multivariable-adjusted mortality 
risks between peritoneal dialysis (PD) and hemodialysis 
(HD) by subgroups (adjusted hazard ratios [HRs] and 95% 
confidence intervals [CIs] for mortality by multivariable-ad-
justed Cox proportional hazard regression analyses). NHI, 
National Health Insurance; MA, Medical Aid; DM, diabetes 
mellitus; MI, myocardial infarction; CHF, congestive heart 
failure; PAD, peripheral artery disease; CVD, cerebrovascu-
lar disease; CPD, chronic pulmonary disease; PUD, peptic 
ulcer disease; LD, liver disease.
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Table 2. Multivariable-adjusted likelihood to choose dialysis modality according to baseline comorbid conditions in all inci-
dent dialysis patients
Baseline comorbid condition Odds ratio (95% CI)a p value
More likely to choose PD as an initial dialysis modality
Myocardial infarctionb 1.61 (1.41–1.83) < 0.001
Congestive heart failureb 1.20 (1.11–1.29) < 0.001
Diabetes mellitusb 1.13 (1.07–1.19) < 0.001
Chronic pulmonary disease 1.04 (0.97–1.11) 0.310
More likely to choose HD as an initial dialysis modality
Cancer 1.49 (1.32–1.69) < 0.001
MA (vs. NHI)b 1.22 (1.13–1.32) < 0.001
Sex, male (vs. female)b 1.17 (1.11–1.23) < 0.001
Cerebrovascular diseasec 1.14 (1.05–1.23) 0.003
Liver disease 1.10 (1.01–1.20) 0.031
Peptic ulcer disease 1.04 (0.97–1.13) 0.221
Peripheral artery disease 1.04 (0.93–1.16) 0.543
Age (per 1-year increase)c 1.02 (1.02–1.02) < 0.001
CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health Insurance.
aAdjusted odds ratios and 95% CIs by multivariable-adjusted logistic regression analysis for choosing each dialysis modality. 
bThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
cThe pattern of choice for dialysis modality in this condition consequently conferred the survival benefit.
Figure 2. The pattern of choosing dialysis modality accord-
ing to baseline comorbid conditions and related mortality 
outcomes. Black bars: multivariable-adjusted likelihood to 
choose dialysis modality according to baseline comorbid 
conditions in all incident dialysis patients (adjusted odds 
ratios and 95% conf idence intervals [CIs] by multivari-
able-adjusted logistic regression analysis for choosing each 
dialysis modality). Red bars: multivariable-adjusted like-
lihood to experience more harm from one modality than 
from the other modality in all incident dialysis patients (ad-
justed synergy factors and 95% CIs based on a multiplicative 
interaction between initial dialysis modality and baseline 
comorbid conditions on mortality). Red shaded area: the 
pattern of choice for dialysis modality in this condition 
consequently increased the mortality risk (p < 0.05). Blue 
shaded area: the pattern of choice for dialysis modality in 
this condition consequently conferred the survival benefit (p 
< 0.05). MA, Medical Aid; NHI, National Health Insurance; 
HD, hemodialysis; PD, peritoneal dialysis.
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modality in both physicians and patients, but various 
other factors are also involved. 
During the study period, patients with diabetes, MI, or 
CHF had a significantly higher likelihood of being re-
garded as proper candidates for initiating dialysis thera-
py with PD, but all of these comorbid conditions syner-
gistically increased the intrinsic mortality risk posed by 
PD per se. On the other hand, even though Medical Aid 
as primary insurance and male gender led to avoidance 
of PD as an initial dialysis modality, those conditions 
were found to significantly decrease the mortality risk 
conferred by PD per se (increased mortality risk with 
Table 3. Multivariable-adjusted likelihood to experience more harm from one modality than from the other modality in all 
incident dialysis patients
Baseline comorbid condition SF (95% CI)a p value
More harm from PD as an initial dialysis modality
Cerebrovascular diseaseb 1.25 (1.11–1.42) < 0.001
Myocardial infarctionc 1.23 (1.02–1.48) 0.031
Diabetes mellitusc 1.20 (1.08–1.32) 0.001
Congestive heart failurec 1.09 (1.06–1.34) 0.003
Peptic ulcer disease 1.07 (0.93–1.22) 0.346
Chronic pulmonary disease 1.05 (0.93–1.19) 0.394
Peripheral artery disease 1.05 (0.87–1.26) 0.641
Age (per 1-year increase)b 1.01 (1.00–1.01) < 0.001
More harm from HD as an initial dialysis modality
MA (vs. NHI)c 1.26 (1.10–1.44) 0.001
Cancer 1.14 (0.94–1.37) 0.182
Sex, male (vs. female)c 1.11 (1.00–1.22) 0.047
Liver disease 1.10 (0.94–1.28) 0.249
SF, synergy factor; CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health 
Insurance.
aAdjusted SFs and 95% CIs based on a multiplicative interaction between initial dialysis modality and baseline comorbid con-
ditions on mortality. 
bThe pattern of choice for dialysis modality in this condition consequently conferred the survival benefit.
cThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
Table 4. Multivariable-adjusted likelihood to choose PD as an initial dialysis modality according to the number and severity of 
comorbidities measured by CCI in all incident dialysis patients
Baseline comorbid condition Odds ratio (95% CI)a p value
More likely to choose PD as an initial dialysis modality
With no comorbidity 1.00 (reference) -
With ≥ 1 comorbidity 1.04 (0.97–1.12) 0.307
The severity of comorbidities measured by CCI
0 1.00 (reference) -
1 1.04 (0.96–1.13) 0.347
2 1.09 (0.99–1.20) 0.088
≥ 3 0.96 (0.87–1.06) 0.438
PD, peritoneal dialysis; CCI, Charlson comorbidity index; CI, confidence interval.
aAdjusted odds ratios and 95% CIs by multivariable-adjusted logistic regression analysis for choosing each dialysis modality.
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HD). A preferred implementation of PD for patients 
with diabetes has also been documented in several pre-
vious reports [3,17-19]. This finding can be explained by 
the belief in the potential advantages of PD over HD for 
maintaining more stable hemodynamic status, particu-
larly under diabetes-related autonomic dysfunction and 
the absence of requirements for usable vascular access, 
which is difficult to achieve due to diabetes-related ath-
erosclerotic calcification. However, contrary to this view 
but in accordance with our study, a large proportion of 
studies to date indicate that PD is associated with worse 
outcomes than HD when performed in diabetic patients 
[20-22]. Whether diabetes per se should be recognized as 
a contraindication to the use of PD remains highly con-
troversial and far from being definitively answered [23]. 
In addition, a considerable number of studies have 
suggested that PD has possible advantages compared 
to HD in patients with underlying cardiac dysfunction. 
In particular, patients with medical treatment-resis-
tant CHF have few therapeutic options other than heart 
transplantation, surgical plasty, or extracorporeal ultra-
filtration. In such cases, short-term use of PD provides 
symptomatic relief and improvement of various cardiac 
indices [24,25]. In a similar way, PD is regarded as also 
having potential benefits for patients with coronary ar-
tery disease. Partly due to less abrupt hemodynamic dis-
turbance than HD, PD is associated with a low probabil-
ity of development of myocardial stunning represented 
by regional wall motion abnormalities, which are fre-
quently observed in HD [26]. However, these inferences 
are based on small-scale observations that are neither 
adequately validated nor were evidenced in large-scale 
studies; rather, dialysis initiation with PD is associated 
Table 5. Multivariable-adjusted likelihood to experience more harm with PD as an initial dialysis modality according to the 
number and severity of comorbidities measured by CCI in all incident dialysis patients
Baseline comorbid condition SF (95% CI)a p value
More harm from PD as an initial dialysis modality
With no comorbidity 1.00 (reference) -
With ≥1 comorbidity 1.40 (1.20–1.64) < 0.001
The severity of comorbidities measured by CCI
0 1.00 (reference) -
1 1.30 (1.06–1.60) 0.011
2 1.48 (1.23–1.78) < 0.001
≥ 3 1.46 (1.24–1.72) < 0.001
p for trendb - < 0.001
PD, peritoneal dialysis; CCI, Charlson comorbidity index; SF, synergy factor; CI, confidence interval.
aAdjusted SFs and 95% CIs based on a multiplicative interaction between initial dialysis modality and the number/severity of 
comorbidities on mortality.
bThe linear trend in an increase in the mortality risk with PD vs. hemodialysis (reference) from CCI = 0 to CCI ≥ 3.
≥ 1  Comorbidities
vs. no comorbidity
CCI ≥ 3
0 0.5
More likely to
choose HD
More likely to
choose PD
1.0 1.5 2.0
CCI = 2
CCI = 1
CCI = 0
Figure 3. Multivariable-adjusted likelihood to choose peri-
toneal dialysis (PD) as an initial dialysis modality according 
to the number and severity of comorbidities measured by 
Charlson comorbidity index (CCI) in all incident dialysis 
patients (adjusted odds ratios and 95% confidence intervals 
by multivariable-adjusted logistic regression analysis for 
choosing each dialysis modality). HD, hemodialysis. 
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with significantly higher mortality risk than with HD in 
incident ESRD patients with underlying CHF [5,27] or 
coronary artery disease [4]. Supporting these findings, 
a substantial number of studies have suggested that PD 
might be related to a greater atherogenic vascular risk 
than HD given a higher prevalence of dyslipidemia [28], a 
higher level of atherogenic lipoprotein(a) [29], and a high-
er prevalence of overhydration-related high blood pres-
sure [30,31]. Continuous exposure to high glucose load 
induced by PD fluid might also contribute to PD-related 
cardiac compromise, possibly mediated through hyper-
insulinemia with insulin resistance, hyperleptinemia, or 
inflammation with oxidative stress [32,33]. On the other 
hand, older patients or those with prior CVD were more 
likely to choose HD as an initial dialysis modality, and 
this trend in choice consequently conferred a surviv-
al benefit. Consistent with this, the relative advantages 
of HD over PD in elderly patients have been shown in 
previous reports [17,34], particularly in those with dia-
betes or longer dialysis vintage [35]. The cause of higher 
mortality with PD versus HD in elderly patients is not 
clear. However, it should be noted that cardiovascular 
mortality, as the most common cause of general ESRD 
patients, cannot solely account for this; rather, as the age 
of ESRD patients increases, noncardiovascular causes 
of mortality were more predominant than cardiovas-
cular causes [20]. This pattern is especially apparent in 
PD-treated patients with diabetes, female gender, and 
advanced age [34]. In addition, partly due to functional 
impairments in handling PD equipments including PD 
solution exchange, and in performing PD-related self-
care, patients with CVD are not only less likely to ini-
tiate dialysis treatment with PD but also have potential 
disadvantages that can lead to PD-related adverse out-
comes. In a long-term follow-up study of the patients 
who experienced a stroke, the most common cause of 
death was cardiovascular disease, with a rate of 67.4% 
[36]. This high atherosclerotic burden prior to and post 
stroke might not only be further complicated by the 
abovementioned metabolic derangements induced by 
PD, but also independently associated with an increased 
risk of PD peritonitis, which is an independent predic-
tor of mortality [37,38]. 
When analyzed by age (≥ 60 years vs. < 60 years), we can 
observe that, as age increases, the number of comorbid 
conditions as well as the degree of risk increase inde-
pendently related to the choice of a particular dialysis 
modality was decreased, suggesting that age itself might 
serve as the primary prognostic factor. However, under-
lying cardiac morbidities such as MI or CHF was con-
sistently synergistically increased the risk of mortality 
when initiating dialysis treatment with PD, irrespective 
of age groups. 
In this study, we also found that the number or severi-
ty of comorbidities was not a determinant of the dialysis 
modality choice. However, increased mortality was ob-
served in a significant linear trend when patients with a 
higher comorbidity initiated dialysis with PD compared 
to HD (p for trend < 0.001). The distribution of the de-
gree of comorbidities measured by CCI or other param-
eters between incident patients on HD and PD is not 
consistent across studies. It has been reported that, in 
Canada, the United States, and Europe, patients with a 
higher comorbidity level tend to start dialysis therapy 
a≥ 1  Comorbidities
vs. no comorbidity
aCCI ≥ 3
0 0.5
More harm 
from HD
More harm 
from PD
1.0 1.5 2.0
aCCI = 2
p 
fo
r t
re
dn
d 
< 
0.
00
1
aCCI = 1
 CCI = 0
Figure 4. Multivariable-adjusted likelihood to experience 
more harm with peritoneal dialysis (PD) as an initial dial-
ysis modality according to the number and severity of co-
morbidities measured by Charlson comorbidity index (CCI) 
in all incident dialysis patients (adjusted synergy factors 
and 95% confidence intervals based on a multiplicative in-
teraction between initial dialysis modality and the number/
severity of comorbidities on mortality). HD, hemodialysis. 
aThe increases in the number of comorbidities (≥ 1 comor-
bidities vs. no comorbidity) and CCI scores signif icantly 
associated with the increase in mortality when accompanied 
by PD as an initial dialysis modality (p < 0.05).
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with HD instead of PD [6,18,19,39], whereas, in Colum-
bia, incident PD patients have a significantly higher de-
gree of comorbidity than HD patients [40]. How dialysis 
modalities modify the mortality risk according to the 
degree of comorbidities has also been investigated in 
a few studies. In agreement with our findings, studies 
investigating the European ERA-EDTA (The European 
Renal Association-European Dialysis and Transplant 
Association) and Australia and New Zealand registries 
commonly showed the superiority of PD over HD for 
survival in patients with no comorbidity, but this effect 
disappears as the number of comorbidities increases 
[6,41]. Also in a large Taiwanese cohort stratified by CCI 
score, the patients belonging to the group with the high-
est CCI score had a significant 21% higher mortality risk 
with PD than with HD [42].
When focusing on HD, we found that patients who 
were male and had Medical Aid as their primary in-
surance were significantly more likely to start dialysis 
treatment with HD, but this choice was associated with 
an increase in mortality risk. The trend that incident 
ESRD patients on PD were of higher socioeconomic sta-
tus than those on HD was in accordance with previous 
studies [18,39]. This difference may result from several 
parameters that are difficult to measure, such as hygiene 
status, accessibility to medical service, or reimburse-
ment factors [43]. 
We should note the limitations of this study and nec-
essary precautions in interpreting the results. First, since 
the comorbidities listed in this study were assessed by 
reviewing the diagnosis codes claimed, the possibility of 
underestimation or oversimplification of the comorbid-
ity burden or of missing the effects of other important 
conditions not addressed in this study could not be ex-
cluded. Second, due to the limitations of the dataset, we 
could not access either the causes of death or the infor-
mation on dialysis-related factors potentially affecting 
patients’ mortality such as HD adequacy, nutritional 
status, infection rates, or other non-conventional risk 
factors. Fourth, and most importantly, we focused only 
on the relative degrees of advantage or disadvantage of 
one modality versus the other modality using SF based 
on multiplicative interaction analyses. Therefore, cau-
tion is required when interpreting the results.
In conclusion, we found that some types and sever-
ity of comorbidities exerted independent effects on 
the choice of dialysis modality, but this choice did not 
always lead to the best outcomes. Based on our obser-
vations, the overall worse outcomes of incident PD pa-
tients compared to HD patients during the study period 
might result from, at least in part, more frequent use of 
PD in the patients with prior MI, CHF, diabetes or with 
a higher degree of comorbidity. To improve the survival 
rate of dialysis patients, further intensive investigation 
of the pattern of choosing dialysis modality according 
to baseline comorbid and other conditions, and reviews 
of the related consequences on mortality outcomes are 
warranted.
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Supplementary Table 1. Multivariable-adjusted likelihood to choose dialysis modality according to baseline comorbid condi-
tions in incident dialysis patients aged less than 60 years
Baseline comorbid condition Odds ratio (95% CI)a p value
More likely to choose PD as an initial dialysis modality
Myocardial infarctionb 1.33 (1.06–1.67) 0.015
Congestive heart failure 1.17 (1.05–1.29) 0.003
Chronic pulmonary disease 1.15 (1.04–1.27) 0.008
Diabetes mellitusb 1.13 (1.05–1.21) 0.001
More likely to choose HD as an initial dialysis modality
MA (vs. NHI)b 1.28 (1.16–1.40) < 0.001
Sex, male (vs. female) 1.23 (1.15–1.31) < 0.001
Cancer 1.22 (1.03–1.45) 0.019
Peripheral artery disease 1.06 (0.89–1.26) 0.507
Liver disease 1.06 (0.95–1.17) 0.311
Cerebrovascular disease 1.05 (0.92–1.19) 0.452
Peptic ulcer disease 1.03 (0.93–1.14) 0.559
Age (per 1-year increase)c 1.02 (1.01–1.02) < 0.001
CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health Insurance. 
aAdjusted odds ratios and 95% CIs by multivariable-adjusted logistic regression analysis for choosing each dialysis modality. 
bThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
cThe pattern of choice for dialysis modality in this condition consequently conferred the survival benefit.
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Supplementary Table 2. Multivariable-adjusted likelihood to experience more harm from one modality than from the other 
modality in incident dialysis patients aged less than 60 years 
Baseline comorbid condition SF (95% CI)a p value
More harm from PD as an initial dialysis modality
Myocardial infarctionb 1.52 (1.00–2.29) 0.049
Cerebrovascular disease 1.46 (1.15–1.83) 0.001
Diabetes mellitusb 1.23 (1.04–1.47) 0.018
Congestive heart failure 1.20 (0.97–1.47) 0.094
Cancer 1.09 (0.83–1.44) 0.532
Age (per 1-year increase)c 1.01 (1.00–1.02) 0.016
Sex, male (vs. female) 1.01 (0.85–1.20) 0.889
More harm from HD as an initial dialysis modality
MA (vs. NHI)b 1.42 (1.17–1.73) 0.001
Chronic pulmonary disease 1.08 (0.87–1.35) 0.489
Liver disease 1.02 (0.82–1.28) 0.838
Peripheral artery disease 1.01 (0.69–1.47) 0.977
Peptic ulcer disease 1.00 (0.79–1.26) 0.990
SF, synergy factor; CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health 
Insurance. 
aAdjusted SFs and 95% CIs based on a multiplicative interaction between initial dialysis modality and baseline comorbid con-
ditions on mortality. 
bThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
cThe pattern of choice for dialysis modality in this condition consequently conferred the survival benefit.
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Supplementary Table 3. Multivariable-adjusted likelihood to choose dialysis modality according to baseline comorbid condi-
tions in incident dialysis patients aged 60 years or older
Baseline comorbid condition Odds ratio (95% CI)a p value
More likely to choose PD as an initial dialysis modality
Myocardial infarction 1.77 (1.51–2.08) < 0.001
Congestive heart failureb 1.23 (1.11–1.29) < 0.001
Diabetes mellitus 1.05 (0.96–1.14) 0.273
More likely to choose HD as an initial dialysis modality
Cancerb 1.87 (1.55–2.25) < 0.001
Liver disease 1.22 (1.05–1.42) 0.010
Cerebrovascular disease 1.20 (1.08–1.34) 0.001
MA (vs. NHI) 1.12 (0.98–1.29) 0.090
Sex, male (vs. female)b 1.09 (1.00–1.18) 0.041
Peptic ulcer disease 1.07 (0.95–1.19) 0.272
Chronic pulmonary disease 1.05 (0.95–1.17) 0.315
Age (per 1-year increase) 1.04 (1.03–1.05) < 0.001
Peripheral artery disease 1.02 (0.87–1.19) 0.812
CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health Insurance.
aAdjusted odds ratios and 95% CIs by multivariable-adjusted logistic regression analysis for choosing each dialysis modality. 
bThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
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Supplementary Table 4. Multivariable-adjusted likelihood to experience more harm from one modality than from the other 
modality in incident dialysis patients aged 60 years or older 
Baseline comorbid condition SF (95% CI)a p value
More harm from PD as an initial dialysis modality
Congestive heart failureb 1.17 (1.02–1.35) 0.028
Cerebrovascular disease 1.15 (0.99–1.33) 0.068
Diabetes mellitus 1.15 (1.01–1.30) 0.034
Myocardial infarction 1.13 (0.91–1.40) 0.267
Peripheral artery disease 1.08 (0.87–1.34) 0.469
Peptic ulcer disease 1.07 (0.91–1.26) 0.418
Chronic pulmonary disease 1.06 (0.91–1.22) 0.462
More harm from HD as an initial dialysis modality
Cancerb 1.49 (1.15–1.94) 0.003
Liver disease 1.16 (0.93–1.45) 0.175
Sex, male (vs. female)b 1.16 (1.03–1.31) 0.015
MA (vs. NHI) 1.16 (0.96–1.40) 0.132
Age (per 1-year increase) 1.01 (1.00–1.02) 0.316
SF, synergy factor; CI, confidence interval; PD, peritoneal dialysis; HD, hemodialysis; MA, Medical Aid; NHI, National Health 
Insurance. 
aAdjusted SFs and 95% CIs based on a multiplicative interaction between initial dialysis modality and baseline comorbid con-
ditions on mortality. 
bThe pattern of choice for dialysis modality in this condition consequently increased the mortality risk.
